Coelenteramide

Identification

Name
Coelenteramide
Accession Number
DB04049  (EXPT00888)
Type
Small Molecule
Groups
Experimental
Description
Not Available
Structure
Thumb
Synonyms
Not Available
Categories
UNII
Not Available
CAS number
Not Available
Weight
Average: 411.4525
Monoisotopic: 411.158291553
Chemical Formula
C25H21N3O3
InChI Key
CJIIERPDFZUYPI-UHFFFAOYSA-N
InChI
InChI=1S/C25H21N3O3/c29-20-10-6-18(7-11-20)15-24(31)28-25-22(14-17-4-2-1-3-5-17)27-23(16-26-25)19-8-12-21(30)13-9-19/h1-13,16,29-30H,14-15H2,(H,26,28,31)
IUPAC Name
N-[3-benzyl-5-(4-hydroxyphenyl)pyrazin-2-yl]-2-(4-hydroxyphenyl)acetamide
SMILES
OC1=CC=C(CC(=O)NC2=NC=C(N=C2CC2=CC=CC=C2)C2=CC=C(O)C=C2)C=C1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

Synthesis Reference

Satoshi Inouye, "Process for producing coelenteramide or an analog thereof." U.S. Patent US20100249387, issued September 30, 2010.

US20100249387
General References
Not Available
External Links
KEGG Compound
C15038
PubChem Compound
5326781
PubChem Substance
46506249
ChemSpider
20120243
ChEBI
41487
HET
CEI
Wikipedia
Coelenteramide
PDB Entries
1s36 / 2f8p / 2psj / 4mry / 4n1g

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00277 mg/mLALOGPS
logP4.34ALOGPS
logP4.6ChemAxon
logS-5.2ALOGPS
pKa (Strongest Acidic)9.18ChemAxon
pKa (Strongest Basic)-0.26ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area95.34 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity119.68 m3·mol-1ChemAxon
Polarizability43.98 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9866
Blood Brain Barrier+0.8769
Caco-2 permeable-0.5429
P-glycoprotein substrateNon-substrate0.5719
P-glycoprotein inhibitor INon-inhibitor0.8634
P-glycoprotein inhibitor IINon-inhibitor0.95
Renal organic cation transporterNon-inhibitor0.8992
CYP450 2C9 substrateNon-substrate0.8074
CYP450 2D6 substrateNon-substrate0.7925
CYP450 3A4 substrateNon-substrate0.6079
CYP450 1A2 substrateNon-inhibitor0.6903
CYP450 2C9 inhibitorNon-inhibitor0.57
CYP450 2D6 inhibitorNon-inhibitor0.8894
CYP450 2C19 inhibitorNon-inhibitor0.6425
CYP450 3A4 inhibitorNon-inhibitor0.7663
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5456
Ames testNon AMES toxic0.8234
CarcinogenicityNon-carcinogens0.8707
BiodegradationNot ready biodegradable0.9809
Rat acute toxicity2.3147 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9818
hERG inhibition (predictor II)Non-inhibitor0.8651
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylacetamides. These are amide derivatives of phenylacetic acids.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenylacetamides
Direct Parent
Phenylacetamides
Alternative Parents
N-arylamides / 1-hydroxy-2-unsubstituted benzenoids / Pyrazines / Imidolactams / Heteroaromatic compounds / Secondary carboxylic acid amides / Azacyclic compounds / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives
show 1 more
Substituents
Phenylacetamide / N-arylamide / 1-hydroxy-2-unsubstituted benzenoid / Phenol / Pyrazine / Imidolactam / Heteroaromatic compound / Carboxamide group / Secondary carboxylic acid amide / Carboxylic acid derivative
show 11 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
pyrazines (CHEBI:41487) / a luciferin (OXIDIZED-OPLOPHORUS-LUCIFERIN)

Drug created on June 13, 2005 07:24 / Updated on November 02, 2018 05:49